NEW YORK (GenomeWeb News) – Sengenics and Parkway Laboratory Services have entered into a partnership to offer genetics tests in Singapore, Sengenics said on Thursday.

The deal focuses on Sengenics' CardioSure heart disease test and Sequenom's MaterniT21 Plus non-invasive prenatal diagnostic test. The CardioSure test, Sengenics said, is based on a concept of "Asianized Diagnostics" to include disease biomarkers from Asian ethnic groups as well as those from Caucasian and African populations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.